Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles

References

• Addys G, Roberta de Rosa, Braschi S, Maffei L. (2005). Intranasal administration of nerve growth factor rescues recognition memory deficits in AD-11 anti-NGF transgenic mice. PANS, 10, 3811–3816.
   Google Scholar
• Allen S, Dawbarn D. (2006). Clinical relevance of the neurotrophins and their receptors. Clin Sci, 110, 175–191.
   PubMed Web of Science ®Google Scholar
• Alyautdin RN, Gathier D, Petrov VE, Kharkevich D, Kreuter J. (1995). Analgesic activity of the hexapeptide dalaragin adsorbed on surface of polysorbate-90 coated polybutylcyanoacrylate nanoparticles. Eur J Pharm Biopharm, 41, 44–48.
   Web of Science ®Google Scholar
• Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. (1997). Delivery of loperamide across the blood-brain barrier with polysorbate 80 coated polybutylcyanoacrylate nanoparticles. J Pharm Res, 14, 325–328.
   PubMed Web of Science ®Google Scholar
• Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley D, Kreuter J. (1998). Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80 coated polybutylcyanoacrylate nanoparticles: as in situ brain perfusion study. J Microencapsul, 15, 67–74.
   PubMed Web of Science ®Google Scholar
• Alyautdin RN, Reichel A, Löbenberg R, Ramge P, Kreuter J, Begley D. (2001). Interaction of poly(butylcyanoacrylate) nanoparticles with blood-brain barrier in vivo and in vitro. J Drug Target, 9, 209–221.
   PubMed Web of Science ®Google Scholar
• Alyautdin RN, Kreuter J, Kharkevich DA. (2003). Drug delivery to the brain with nanoparticles. J Exp Clin Pharmacol, 66, 65–68.
   Google Scholar
• Amende I, Kale A, McCue S. (2005). Gait dynamics in mouse models of Parkinson’s disease and Huntington’s disease. J Neuro Eng Rehabilitat, 20, 1186–1199.
   Google Scholar
• Banks WA. (2005). Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des, 11, 973–984.
   PubMed Web of Science ®Google Scholar
• Barde YA. (1989). Trophic factors and neuronal survival. J Neurol, 2, 1525–1534.
   Google Scholar
• Begley DJ. (2003). Understanding and circumventing the blood-brain barrier. Acta Pediatr Suppl, 92, 83–91.
   PubMedGoogle Scholar
• Berger-Sweeney J, Berger UV, Sharma M, Paul CA. (1994). Effects of carbon dioxide-induced anesthesia on cholinergic parameters in rat brain. Lab Anim Sci, 44, 369–371.
   PubMedGoogle Scholar
• Blöchl A, Sirrenberg C. (1996). Neurotrophins stimulate the release of dopamine from rat mesencephalic neurons via Trk and p75Lntr receptors. J Biol Chem, 271, 21100–21107.
   PubMed Web of Science ®Google Scholar
• Bonner LT, Peskind ER. (2002). Pharmacologic treatments of dementia. Med Clin North Am, 86, 657–674.
   PubMed Web of Science ®Google Scholar
• Bonuccelli U, Del Dotto P. (2006). New pharmacologic horizons in the treatment of Parkinson disease. Neurology, 67, 30–38.
   Web of Science ®Google Scholar
• Burns RS, LeWitt PA, Ebert MH. (1985). The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med, 312, 1418–1421.
   PubMed Web of Science ®Google Scholar
• Castellenos-Ortega MR, Cruz-Aguado R, Martinez-Marty L. (1999). Nerve growth factor: possibilities and limitations of its clinical application. Rev Neurol, 29, 439–471.
   PubMed Web of Science ®Google Scholar
• Collier TJ, Sortwell CE. (1999). Therapeutic potential of nerve growth factors in Parkinson’s disease. Drugs Aging, 4, 261–287.
   Google Scholar
• Couvreur P, Kante B, Roland M, Guiot P, Bauduin P, Speiser P. (1979). Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J Pharm Pharmacol, 31, 331–332.
   Web of Science ®Google Scholar
• Eggert K, Schlegel J, Oertel W. (1999). Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity. Neurosci Lett, 269, 178–182.
   PubMed Web of Science ®Google Scholar
• Garcia E, Rios C, Sotelo J. (1992). Ventricular injection of nerve growth factor increases dopamine content in the striata of MPTP-treated mice. Neurochem Res, 17, 979–982.
   PubMed Web of Science ®Google Scholar
• Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. (1999). Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res, 16, 1564–1569.
   PubMed Web of Science ®Google Scholar
• Hefti F. (1983). Alzheimer’s disease caused by a lack of nerve growth factor. Ann Neurol, 13, 109–110.
   PubMed Web of Science ®Google Scholar
• Hirsch EC, Hunot S, Faucheux B, (1999). Dopaminergic neurons degenerate by apoptosis in Parkinson’s disease. Mov Disord, 14, 383–385.
   PubMed Web of Science ®Google Scholar
• Kawamata T, Yamaguchi T, Shinya K, Hori T. (2003). Divergence in signaling pathways involved in promotion of cell viability mediated by bFGF, NGF and EGF in PC12 cells. Neurochem Res, 28, 1221–1225.
   PubMed Web of Science ®Google Scholar
• Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev, 47, 65–81.
   PubMed Web of Science ®Google Scholar
• Kreuter J. (2006). Nanoparticles as drug delivery systems for the brain. In: Benita S. (Ed.), Microencapsulation. Methods and Industrial Applications (2nd ed., pp. 689–706 ). New York: Taylor and Francis.
   Google Scholar
• Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. (2002). Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target, 10, 317–325.
   PubMed Web of Science ®Google Scholar
• Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K. (2007). Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Control Release, 118, 54–58.
   PubMed Web of Science ®Google Scholar
• Liao GS, Li XB, Zhang CY, Shu YY, Tang SX. (2001). Pharmacological actions of nerve growth factor-transferrin conjugate on the central nervous system. J Nat Toxins, 10, 291–297.
   PubMedGoogle Scholar
• Lockman PR, Mumper RJ, Khan MA, Allen DD. (2002). Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm, 28, 1–13.
   PubMed Web of Science ®Google Scholar
• Mashayekhi F, Salehi Z. (2007). Infusion of anti-nerve growth factor into the cisternum magnum of chick embryo leads to decrease cell production in the cerebral cortical germinal epithelium. Eur J Neurology, 14, 181–186.
   PubMed Web of Science ®Google Scholar
• Muralikrishnan D, Samantaray S, Mohanakumar KP. (2003). D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity. Synapse, 50, 7–13.
   PubMed Web of Science ®Google Scholar
• Petkov VD, Mosharrof AH, Petkov VV. (1988). Comparative studies on the effects of the nootropic drugs adafenoxate, meclofenoxate and piracetam, and of citicholine on scopolamine-impaired memory, exploratory behavior and physical capabilities (experiments on rats and mice). Acta Physiol Pharmacol Bulg, 14, 3–13.
   PubMedGoogle Scholar
• Petri B, Bootz A, Khalansky A, Hekmatara T, Müller R, Uhl R, Kreuter J, Gelperina S. (2007). Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Release, 117, 51–58.
   PubMed Web of Science ®Google Scholar
• Randerson J. (2003). Nerve growth factor shows promise in Parkinson’s disease. New Scientist, 2389, 20–27.
   Google Scholar
• Rinne JO, Rummukainen J, Paijarvi L, Rinne UK. (1989). Dementia in Parkinson’s disease is related to neuronal loss in the medial substantia nigra. Ann Neural, 26, 47–50.
   PubMed Web of Science ®Google Scholar
• Schmidt N, Ferger B. (2001). Neurochemical findings in the MPTP model of Parkinson’s disease. J Neural Transm, 108, 1263–1282.
   PubMed Web of Science ®Google Scholar
• Salinas M, Diaz R, Abraham N, Carlos M, Ruiz de Galarreta, Cuadrado A. (2003). Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner. J Biol Chem, 278, 13898–13904.
   PubMed Web of Science ®Google Scholar
• Schindowski K, Belarbi K, Buée L. (2008). Neurotrophic factors in Alzheimer’s disease: role of axonal transport. Genes Brain Behav, 7, 43–56.
   PubMed Web of Science ®Google Scholar
• Siegel GJ, Chauhan NB. (2000). Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain. Brain Res Rev, 33, 199–227.
   PubMed Web of Science ®Google Scholar
• Shimoke K, Chiba H. (2001). Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutic application for Parkinson’s disease. J Neurosci Res, 63, 402–409.
   PubMed Web of Science ®Google Scholar
• Steiniger SCJ, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, Gelperina SE. (2004). Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer, 109, 759–767.
   PubMed Web of Science ®Google Scholar
• Sykiotis GP, Papavassiliou AG. (2007). Targeting the nerve growth factor network in Alzheimer’s disease. Expert Opin Investig Drugs, 16, 267–269.
   PubMed Web of Science ®Google Scholar
• Teismann P, Schulz JB. (2004). Cellular pathology of Parkinson’s disease: astrocytes, microglia and inflammation. Cell Tissue Res, 318, 149–161.
   PubMed Web of Science ®Google Scholar
• Tuszynski MN, Berardi N, Cattaneo A. (1996). Nerve growth factor delivery by gene transfer induces differential outgrowth of sensory, motor and noradrenergic neuritis after adult spinal cord injury. Exp Neurol, 137, 157–173.
   Google Scholar
• Tyler WJ, Perrett, Pozzo-Miller LD. (2002). The role of neurotrophins in neurotransmitter release. Neuroscience, 8, 524–531.
   Google Scholar
• Val’dman EA, Kapitsa IG, Nerobkova LN, Aksenova LN, Buneeva OA, Medvedev AE. (2004). The effect of long-term administration of isatin and himantan to mice on sensitivity of brain monoamine oxidase B to inhibition by deprenyl in vivo and in vitro. Biomed Khim, 50, 509–513 [Article in Russian].
   PubMedGoogle Scholar
• Vasir JK, Reddy MK, Labhasetwar VD. (2005). Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci, 1, 47–64.
   Web of Science ®Google Scholar
• Vila M, Jackson-Lewis V, Guégan C, Wu DC, Teismann P, Choi DK, Tieu K, Przedborski S. (2001). The role of glial cells in Parkinson’s disease. Curr Opin Neurol, 14, 483–489.
   PubMed Web of Science ®Google Scholar
• Wyman TC, Rohrer DC, Kirigiti P, Nichols HV, Pilcher KY, Nilaver G, Machida CA. (1999). Promoter-activated expression of nerve growth factor for treatment of neurodegenerative diseases. Gene Ther, 10, 1648–1660.
   Google Scholar